News

Can-Fite has already secured the FDA’s Orphan Drug designation for CF102, which is a small orally bioavailable drug that binds with high affinity and selectivity to the A3

Under the deal, if the company meets Phase 3 trial design objectives, it can seek regulatory approval of both TG-1101 and TGR-1202 in combination. The company will release

Vivolux said vast amounts of defective proteins formed in tumor cells disrupt the functioning of proteasome. The new mechanism of action by VLX1570 has been indicated to inhibit

Entresto is indicated to lower the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction (HfrEF). It improves the protective neurohormonal systems

Appreciating the importance of the U.S. biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc.

It is the result of over 150 million euro worth of investment with creation of 100 highly skilled jobs. In attendance at the event were Austrian dignitaries from

The alliance will combine Clinigen’s and Cumberland’s respective strengths, expertise and geographical footprints to maximize the commercial potential of future products. As part of Clinigen’s continuing strategy to

his announcement was made at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, September 16-19, 2015 in New York, NY. VISTA (V-Domain Ig Suppressor of

Amgen has agreed to acquire all outstanding shares of Dezima for up to $1.55bn from Forbion and other current shareholders, subject to obtaining U.S. Federal Trade Commission clearance.